

Plan ahead for the 2024/2025 RSV season

Introducing the Beyfortus® (nirsevimab-alip) Reservation Program

RSV, respiratory syncytial virus.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

- **Hypersensitivity Including Anaphylaxis:** Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information at [Beyfortus.com](https://www.beyfortus.com)

 **Beyfortus**®
(nirsevimab-alip) | 50 mg
100 mg
Injection

sanofi

The Beyfortus[®] Reservation Program


Optimizing your planning for the 2024/2025 RSV season

The Beyfortus reservation program provides critical insight on customer demand, and we are committed to prioritizing fulfillment of requests placed through this program.

With AstraZeneca, we are expanding the Beyfortus manufacturing network to allow for a significant increase in supply for the 2024/2025 season and cover the entire US demand. In addition, we are producing Beyfortus well in advance of the RSV season, with the vast majority of doses available by October.

The Beyfortus Reservation Program will help to optimize planning and provide access to reserve Beyfortus ahead of the season.

How the program works



Opportunities to order outside of the Reservation Program will remain available from September 2024 through February 2025.

This brochure will give you full details on the Beyfortus Reservation Program and how you can participate

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

- **Hypersensitivity Including Anaphylaxis:** Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

Please see additional Important Safety Information throughout this brochure, and full Prescribing Information at Beyfortus.com

Plan ahead for 2024 to qualify for the Reservation Program

Your Sanofi representative is there to help

- Beginning **February 5 and running through April 30**, work with your Sanofi representative to accurately predict and submit the amount of Beyfortus[®] you will need using the Beyfortus Forecast Tool
- Leveraging your historical 2023 birth data, the Sanofi representative will help estimate your total doses of 50 mg and 100 mg each as appropriate for your practice, and will generate a summary for your records

Using the Forecast Tool

The Forecast Tool will help predict your Beyfortus needs for the upcoming RSV season

To help calculate the doses you'll need for a full RSV season, you will input:

- An estimate of the number of newborns you see monthly based on your 2023 EHR data
- The anticipated immunization rate for these births in your practice
- The percentage of publicly insured patients you see

Legend
Inputs Calculations

Customer Information

Account Name: **ABC Pediatrics**
 Contact Name: **First Name**
 Customer Email: **FirstName.LastName@ABC.com**
 Zip Code: **00000**

Inputs
 Recommended to use precise 2023 data related to inputs where possible. For example, consider using EHR data to complete these fields.
 Please note: the data below represents when a baby is born.

# of Births	Apr-24	May-24	Jun-24	Jul-24	Aug-24	Sep-24	Total	Immunization Rate
	10	10	10	10	10	10	60	100%

# of Births	Oct-24	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Total	Immunization Rate	Total Births
	10	10	10	10	10	10	60	100%	120

Patient Population Split

% Publicly Insured: **50%**
 % Privately Insured: **50%**

2nd Season Eligible

For illustrative purposes only.

After inputting and submitting your forecast, the Sanofi representative will send a summary for your records

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

- Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see additional Important Safety Information throughout this brochure, and full Prescribing Information at Beyfortus.com

Place your order and schedule your shipment

The reservation period runs from July 1 through August 31, 2024

Once you have qualified for the program by estimating and submitting your Beyfortus[®] forecast, you will be able to take part in the reservation period and receive program benefits

To reserve your supply, you can go to vaccineshop.com during the reservation period or work with your Sanofi representative.

The Reservation Program offers flexibility based on your needs:

- Determine the timing of your shipments throughout the RSV season
- Orders placed during the reservation period can be made for any amount, but note they cannot exceed +10% from what you forecasted and submitted with your Sanofi representative
- There is no minimum order required to participate

Program not available for Vaccines for Children (VFC) orders. Total order availability may be dependent on overall demand.

The Reservation Program unlocks additional benefits, including:

- Priority shipping, with reserved doses set aside
- Ability to determine your preferred monthly shipment schedule throughout the RSV season
- 90-day payment terms
- Cancellation is possible up to 14 days prior to scheduled shipments*

*Contact Customer Service in order to cancel your order.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

- **Hypersensitivity Including Anaphylaxis:** Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

Please see additional Important Safety Information throughout this brochure, and full Prescribing Information at Beyfortus.com

Advantages of participating in the Reservation Program

Deliveries begin late August/early September 2024

If you placed your order during the reservation period, shipments will begin to arrive as early as August 2024, with additional shipments arriving as you scheduled through February of 2025.

- After the reservation period ends, cancellation of scheduled shipments are allowed for up to 14 days prior to scheduled shipment of doses
- Returns are also accepted on expired product

The Reservation Program has benefits, but it's not your only chance to order

Orders can be placed outside of the Reservation Program during the normal order window from September 2024 through February 2025.

- Go to vaccineshop.com and place an order as you usually would beginning in September
- Normal ordering window terms and conditions:
 - Order Now/Ship Now Only: no ability to schedule future shipments
 - Payment terms are limited to 60 days

Start planning for the 2024/2025 RSV season

**Talk with your Sanofi representative or visit Beyfortus.com
to request a representative for assistance**

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see additional Important Safety Information throughout this brochure, and full Prescribing Information at Beyfortus.com

Frequently asked questions

Qualification and access to the program

1. How is the Beyfortus[®] Reservation Program different from the flu prebooking process?

- Taking part in the Beyfortus Reservation Program is not mandatory in order to receive Beyfortus doses during RSV season
- The RSV Reservation Program offers flexibility and offers minimal commitment due to timing and ability for customers to adjust orders or cancel within terms

2. How do I get access to the Order Forecast Tool and the Reservation Program (particularly without a Sanofi representative)?

- Contact your Sanofi representative to complete and submit the Order Forecast Tool. If you don't already have a representative, you can request one on the [Beyfortus.com](https://www.beyfortus.com) website (either a field-based representative or Customer Service) to participate in the program

3. If I don't use the Order Forecast Tool, am I able to take advantage of the reservation period?

- No, the purpose of the Order Forecast Tool is to help inform providers of the amount of 50 mg and 100 mg doses they may need for the 2024/2025 RSV season. This step must be completed and submitted in order to access the reservation period where doses can be reserved and ordered

4. Is this program applicable to product being ordered through the Vaccines for Children (VFC) program?

- No, this is not applicable to VFC; it applies to direct orders from providers to Sanofi only. Sanofi is engaging with the Centers for Disease Control and Prevention (CDC) for public orders

5. Is there a different approach for providers in the universal states that won't be purchasing product through private purchase?

- The Order Forecast Tool can still be used by providers in these states as it is a helpful tool for planning purposes
- Universal states should engage with the CDC for public orders. Sanofi representatives are only responsible for commercial orders and will not be responsible for any doses ordered through public programs (ie, VFC)

Frequently asked questions (cont'd)

Using the Order Forecast Tool

1. Is Sanofi using the Order Forecast Tool to inform total doses needed for the market?

- Sanofi is committed to producing substantially more doses for the upcoming 2024/2025 season and will use data from the Order Forecast Tool to help inform the overall demand for the 50 mg and 100 mg doses

2. What does my completion of the Order Forecast Tool guarantee?

- Eligibility to participate in the reservation phase and receive promotional terms for doses reserved during that phase. These terms include access to 90-day payment terms, flexibility to schedule doses monthly through RSV season beginning mid-August, and shipping priority for doses
- It is important to note that completion of the tool doesn't guarantee that the doses calculated for public or private needs will be available for reservation during Phase 2

3. When using the Order Forecast Tool, will I also be able to account for doses for children eligible to receive Beyfortus[®] entering their second RSV season?

- Yes, the Order Forecast Tool will allow you to account for doses for children eligible for a second-season dose

4. How should I predict my need given uncertainty around hospital in-season dosing and use of maternal immunization (MI)?

- It is recommended that providers use the Order Forecast Tool based only on their own total births, not taking into account other potential avenues for infants to obtain RSV immunization, such as birthing hospitals or MI

Frequently asked questions (cont'd)

General ordering questions

1. Can I order a different amount than my forecasted total?

- Yes, you can place an order for a different amount, but it cannot exceed +10% over what you forecasted and submitted with your Sanofi representative for each dose (50 mg and 100 mg)

2. Can the shipping schedule or total volume of reserved doses be changed once my order is placed?

- The order amounts and shipment schedule cannot be changed once submitted. If circumstances change and you wish to cancel your order, please contact Customer Service

3. If I don't participate in the Reservation Program, will I still be able to access Beyfortus[®]?

- Yes, it will still be possible to place orders during the normal ordering window, which will be fulfilled in a "order now, ship now" fashion. However, these orders will not receive shipping priority and will be subject to supply availability

 **Beyfortus**[®] | 50 mg
(nirsevimab-alip) | 100 mg
Injection

The Beyfortus[®] Reservation Program

Optimize access for the 2024/2025 RSV season

- **Plan for the Beyfortus doses you'll need:** determine your total doses needed as well as the amounts of each dose (50 mg and 100 mg)
- **Order and enjoy benefits** including shipping priority, 90-day payment terms, and flexibility to schedule doses monthly throughout the RSV season beginning mid-August
- **Schedule desired shipping dates** prior to and during the season

Work with your Sanofi representative to learn more or visit Beyfortus.com to request a representative for any assistance

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

- **Hypersensitivity Including Anaphylaxis:** Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information accompanying this brochure and at Beyfortus.com

sanofi

SANOFI
1 Discovery Drive
Swiftwater, PA 18370

©2024 Sanofi Pasteur Inc. All rights reserved.
MAT-US-2311407-v1.0-01/2024